private investments into oncolytic virus companies in 2016 was nearly 17- fold higher than in the year 2010.
Make an Enquiry: http:// www. marketresearchhub. com / enquiry. php? type = enquiry & re pid = 943738
Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of the open problems regarding the way of administration( intratumoral vs systemic), higher cancer cell specific replication capacity, and longer persistence in vivo. Based on experience with several virus families over the last decades, a few virus families cristallized as well suitable backbones to carry more and more transgenes to express proteins or even single chain antibodies. This would position oncolytic viruses as independent therapeutics and could compete with immunooncology compounds and cancer vaccines.
This report „ The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities“ as of January 2017 brings you up-to-date regarding key players, key technologies, Oncolytic Virus projects, business deals and private and public financing rounds. The report analyzes the Oncolytic Virus pipeline and stakeholders in the field, especially among Big Pharma / Biotech and technology companies. The report highlights the value of oncolytic viruses in terms of partnering terms and conditions, venture and private financing and( initial) public offerings.
Ask For Discount: http:// www. marketresearchhub. com / report / theoncolytic-virus-landscape-2017-an-analysis-of-pipelinestakeholders-deals-industry-trends-opportunitiesreport. html # discount-form
Table of Contents 1 Executive Summary